October 12, 2020
Vigene Biosciences announces today an executive addition. Molly McGlaughlin is appointed as Chief Operation Officer.
October 9, 2020
Vigene has entered a contract manufacturing agreement with Rznomics Inc. for its leading pipeline product, RZ-001. RZ-001 is a gene therapy for advanced hepatocellular carcinoma (HCC).
August 31, 2020
Vigene Biosciences made the 2020 Inc. 5000 list of the fastest-growing private companies in America!
July 22, 2020
Vigene entered an agreement with Altimmune to manufacture its single-dose intranasal vaccine candidate for COVID-19.
Vigene partners with Virovek for cGMP BAC-to-AAV production technology
Virovek has granted Vigene an exclusive cGMP license for their proprietary BAC-to-AAV production technology. AAV vectors generated from this scalable and efficient platform have been proven to infect and transduce a myriad of mammalian cell lines in vitro and a broad range of cell types in vivo.
Get the information you need from our guides and safety data sheets.
Citations & Testimonials
Find out how scientists are using our products and services.